Cadenza Bio develops selective small-molecule drugs for oral administration targeting estrogen receptors to treat demyelinating and inflammatory diseases. The company aims to halt disease progression and promote repair, enhancing the quality of life for patients suffering from debilitating conditions.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Demyelinating and inflammatory diseases lack effective orally administered treatments that can halt disease progression and promote repair. Current therapies often fail to fully address the underlying mechanisms of these conditions, leaving patients with limited options to improve their quality of life.
Solution
Cadenza Bio is developing selective, orally available small-molecule drugs that target estrogen receptors to treat demyelinating and inflammatory diseases. These drugs aim to break the cycle of disease by halting progression, promoting repair, and restoring quality of life. By targeting estrogen receptors, Cadenza Bio's approach seeks to address the underlying mechanisms of these debilitating conditions, offering a potential therapeutic avenue for patients seeking to regain control over their health. The company's mission is to advance therapeutic drugs that will make a meaningful impact on patients' lives.
Target Audience
The primary target audience includes patients suffering from demyelinating and inflammatory diseases, as well as healthcare providers seeking novel therapeutic options for these conditions.
Features
- Orally administered small-molecule drugs for convenient delivery.
- Selective targeting of estrogen receptors to modulate disease pathways.
- Focus on halting disease progression and promoting repair of damaged tissues.
- Designed to improve the quality of life for patients with demyelinating and inflammatory diseases.